Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study

Background Betaine is a major osmolyte, also important in methyl group metabolism. Concentrations of betaine, its metabolite dimethylglycine and analog trimethylamine-N-oxide (TMAO) in blood are cardiovascular risk markers. Diabetes disturbs betaine: does diabetes alter associations between betaine-related measures and cardiovascular risk? Methods Plasma samples were collected from 475 subjects four months after discharge following an acute coronary admission. Death (n = 81), secondary acute MI (n = 87), admission for heart failure (n = 85), unstable angina (n = 72) and all cardiovascular events (n = 283) were recorded (median follow-up: 1804 days). Results High and low metabolite concentrations were defined as top or bottom quintile of the total cohort. In subjects with diabetes (n = 79), high plasma betaine was associated with increased frequencies of events; significantly for heart failure, hazard ratio 3.1 (1.2–8.2) and all cardiovascular events, HR 2.8 (1.4–5.5). In subjects without diabetes (n = 396), low plasma betaine was associated with events; significantly for secondary myocardial infarction, HR 2.1 (1.2–3.6), unstable angina, HR 2.3 (1.3–4.0), and all cardiovascular events, HR 1.4 (1.0–1.9). In diabetes, high TMAO was a marker of all outcomes, HR 2.7 (1.1–7.1) for death, 4.0 (1.6–9.8) for myocardial infarction, 4.6 (2.0–10.7) for heart failure, 9.1 (2.8–29.7) for unstable angina and 2.0 (1.1–3.6) for all cardiovascular events. In subjects without diabetes TMAO was only significant for death, HR 2.7 (1.6–4.8) and heart failure, HR 1.9 (1.1–3.4). Adding the estimated glomerular filtration rate to Cox regression models tended to increase the apparent risks associated with low betaine. Conclusions Elevated plasma betaine concentration is a marker of cardiovascular risk in diabetes; conversely low plasma betaine concentrations indicate increased risk in the absence of diabetes. We speculate that the difference reflects control of osmolyte retention in tissues. Elevated plasma TMAO is a strong risk marker in diabetes.

[1]  S. Hazen,et al.  Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. , 2014, European heart journal.

[2]  P. Ueland,et al.  Assessment of Urinary Betaine as a Marker of Diabetes Mellitus in Cardiovascular Patients , 2013, PloS one.

[3]  P. Ueland,et al.  Plasma Dimethylglycine and Risk of Incident Acute Myocardial Infarction in Patients With Stable Angina Pectoris , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[4]  F. Schliess,et al.  Osmotic regulation of hepatic betaine metabolism. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[5]  F. Bushman,et al.  Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.

[6]  John G Lewis,et al.  Plasma betaine concentrations correlate with plasma cortisol but not with C-reactive protein in an elderly population , 2012, Clinical chemistry and laboratory medicine.

[7]  W. Atkinson,et al.  Betaine and Secondary Events in an Acute Coronary Syndrome Cohort , 2012, PloS one.

[8]  M. Lever,et al.  Variability of plasma and urine betaine in diabetes mellitus and its relationship to methionine load test responses: an observational study , 2012, Cardiovascular Diabetology.

[9]  W. Atkinson,et al.  Plasma Lipids and Betaine Are Related in an Acute Coronary Syndrome Cohort , 2011, PloS one.

[10]  V. Cameron,et al.  Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. , 2011, Journal of molecular and cellular cardiology.

[11]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[12]  M. Lever,et al.  Trimethylaminuria: causes and diagnosis of a socially distressing condition. , 2011, The Clinical biochemist. Reviews.

[13]  M. Lever,et al.  The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. , 2010, Clinical biochemistry.

[14]  W. Atkinson,et al.  Dietary and supplementary betaine: effects on betaine and homocysteine concentrations in males. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[15]  W. Atkinson,et al.  Plasma and urine betaine and dimethylglycine variation in healthy young male subjects. , 2009, Clinical biochemistry.

[16]  Saskia le Cessie,et al.  Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study , 2009, BMJ : British Medical Journal.

[17]  M. Lever,et al.  Plasma dependent and independent accumulation of betaine in male and female rat tissues. , 2009, Physiological research.

[18]  J. Manson,et al.  Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. , 2008, JAMA.

[19]  S. Vollset,et al.  Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. , 2008, The Journal of nutrition.

[20]  R. Clarke,et al.  Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power. , 2007, Clinical chemistry.

[21]  W. Atkinson,et al.  Inter- and intra-individual variations in normal urinary glycine betaine excretion. , 2007, Clinical biochemistry.

[22]  R. Obeid,et al.  Hyperhomocysteinaemia: a critical review of old and new aspects. , 2007, Current drug metabolism.

[23]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[24]  R. Milne,et al.  Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  M. Brosnan,et al.  Effects of diabetes and insulin on betaine-homocysteine S-methyltransferase expression in rat liver. , 2006, American journal of physiology. Endocrinology and metabolism.

[26]  S. Yusuf,et al.  Homocysteine lowering with folic acid and B vitamins in vascular disease. , 2006, The New England journal of medicine.

[27]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[28]  M. Lever,et al.  Aracyl triflates for preparing fluorescent and UV absorbing derivatives of unreactive carboxylates, amines and other metabolites , 2006 .

[29]  M. Lever,et al.  Separation of cationic aracyl derivatives of betaines and related compounds. , 2006, Journal of chromatography. A.

[30]  M. Uusitupa,et al.  Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. , 2006, The Journal of nutrition.

[31]  A. A. Liakishev [Homocysteine lowering with folic acid and B vitamins in vascular disease]. , 2006, Kardiologiia.

[32]  P. Ueland,et al.  Betaine: a key modulator of one-carbon metabolism and homocysteine status , 2005, Clinical chemistry and laboratory medicine.

[33]  B. Breier,et al.  Detection of food intake in a marine mammal using marine osmolytes and their analogues as dietary biomarkers , 2005 .

[34]  M. Lever,et al.  Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. , 2005, Metabolism: clinical and experimental.

[35]  S. Craig,et al.  Betaine in human nutrition. , 2004, The American journal of clinical nutrition.

[36]  C. Frampton,et al.  Short and long-term variation of plasma glycine betaine concentrations in humans. , 2004, Clinical biochemistry.

[37]  C. Vassanelli,et al.  [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[38]  M. Lever,et al.  Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. , 2001, Kidney international.

[39]  D. Häussinger,et al.  Release of osmolytes induced by phagocytosis and hormones in rat liver. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[40]  M. Lever,et al.  Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. , 1999, Diabetes research and clinical practice.

[41]  M. Lever,et al.  Abnormal glycine betaine content of the blood and urine of diabetic and renal patients. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[42]  P J Sadler,et al.  Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. , 1991, Biochimica et biophysica acta.